K-numberK242992
Device nameRayCare (2024A SP1)
ApplicantRaySearch Laboratories AB (PUBL)
Product codeMUJ
Device classClass II
Decision dateApr 17, 2025
DecisionSubstantially Equivalent
Regulation892.5050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

RayCare 2024A SP1 is an oncology information system that manages clinical and administrative workflows for radiation therapy, medical oncology, and surgical oncology. It enables users to define treatment intent, prescribe treatment, plan delivery, manage treatment courses, and monitor progress. The system includes an image viewer for viewing, annotating, registering, and fusing images for offline review of patient positioning during treatment delivery.

Technological characteristics

RayCare 2024A SP1 adds multiple software enhancements to the predicate RayCare 3B, including expanded patient chart features (family history, implantable device lists, social history documentation), PACS archiving support, Python scripting capabilities, improved workflow management with parallel workflow support, updated whiteboard displays, treatment course management functionality, extended diagnosis coding (ICD-0-3), toxicity management, and integration frameworks for treatment devices like Varian TrueBeam.

Test standards cited

Compliance demonstrated with IEC 61217 (radiotherapy equipment coordinates), IEC 62304 (medical device software lifecycle), IEC 62366-1 (usability engineering), and ISO 14971 (risk management). Testing included unit testing, integration testing, system-level testing, cybersecurity testing, usability testing, and regression testing of software verification and validation activities.

Substantial equivalence argument

The subject device maintains the same principle of operation and intended use as the predicate device—both are oncology information systems for managing radiation therapy workflows. Although RayCare 2024A SP1 includes numerous software feature enhancements, these are characterized as incremental improvements rather than fundamental changes to safety or effectiveness. Comprehensive software verification and validation demonstrated that the new features do not raise different questions of safety or effectiveness, and the device performs as well as the predicate. Compliance with recognized consensus standards and successful validation of key features (treatment course management, scripting, treatment recording, and TrueBeam integration) support the determination of substantial equivalence.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →